Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19678564 | 1.00 | ALDH1A1 (0.33) | ALDH1A1KMT2ASMN1; SMN2TP53HBB | |
| SCHEMBL19683919 | 0.84 | SMN1; SMN2 (0.45) | ALDH1A1KMT2ASMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL19683920 | 0.84 | SMN1; SMN2 (0.45) | ALDH1A1KMT2ASMN1; SMN2CYP1A2KDM4E | |
| Methoxymethane SCHEMBL6931778 | 0.70 | — | — | |
| SCHEMBL45142 | 0.67 | — | — | |
| SCHEMBL3841502 | 0.67 | — | — | |
| SCHEMBL5152467 | 0.67 | — | — | |
| SCHEMBL18279951 | 0.67 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2TP53HBBKDM4E | |
| SCHEMBL14410132 | 0.67 | ALDH1A1 (0.47) | ALDH1A1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL14410133 | 0.67 | ALDH1A1 (0.47) | ALDH1A1KMT2ASMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | ALDH1A1 191/4885KMT2A 503/4885SMN1; SMN2 3848/4885 |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | ALDH1A1 191/4885KMT2A 503/4885SMN1; SMN2 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.